T cell mediated hypersensitivity to nickel (Ni 2+ ) is one of the most common causes of allergic contact dermatitis. 
T cell mediated hypersensitivity to nickel (Ni 2+ ) is one of the most common causes of allergic contact dermatitis. Ni 2+ sensitization may also contribute to the failure of Ni 2+ containing joint implants, and revision to non-Ni 2+ containing hardware can be costly and debilitating. Previously, we identified Ni 2+ mimotope peptides, which are reactive to a CD4 + T cell clone, ANi2.3 (Vα1, Vβ17), isolated from a Ni 2+ hypersensitive patient with contact dermatitis. This T cell is restricted to the major histocompatibility complex class II (MHCII) molecule, Human Leukocyte Antigen (HLA)-DR52c (DRA, DRB3*0301 sensitized by patch testing and a positive Ni 2+ LPT. When HLA-typed by a DR52 specific antibody, three out of four patients were DR52 positive. In one patient, Ni 2+ stimulation induced the expansion of Vβ17 positive CD4 + T cells from 0.8% to 13.3%. We found that the percentage of DR52 positivity and Vβ17 usage in Ni 2+ sensitized joint failure patients are similar to Ni sensitized skin allergy patients. Ni 2+ independent mimotope tetramers may be a useful tool to identify the Ni 2+ reactive CD4 + T cells.
Introduction
Nickel (Ni 2+ ) is one of the most common sensitizers according to the American Academy of Dermatology, and was voted 'Allergen of the Year' in 2008. The prevalence of Ni 2+ sensitization has risen from 15.5% in 2009-10, to 18.5% in 2011-12 , and the ATSDR estimates that 10-20% of the US population is sensitized to Ni
2+
. Hypersensitivity to Ni 2+ is an important factor that can cause joint replacements failure;
after such failed implants are replaced with non-Ni 2+ containing hardware, many of the symptoms are relieved (Pacheco, 2015) . Despite the high prevalence of Ni 2+ allergy, the specific immune components of the sensitization process are poorly understood. There is strong evidence for specific T cell involvement in the pathogenesis of the disease, with an expansion of αβ T cells specific for the metal (Sinigaglia et al., 1985; Kapsenberg et al., 1987; Emtestam et al., 1989; Silvennoinen-Kassinen et al., 1991) . Vβ17 elements in Ni 2+ specific human T cell receptors dominate in contact dermatitis, and the frequency of these T cells correlates with the severity of the dermatitis (Vollmer et al., 1997) . In a Ni 2+ reactive CD4 + T cell transfectoma-ANi2.3, derived from a subject with Ni 2+ induced contact dermatitis, MHCII molecule DR52c (DRA*0101, DRB3*0301) interacts with the T cell receptor (TCR) (Vα1, Vβ17) in complex with an unknown peptide (Lu et al., 2003) . We found several peptide mimotopes that, when bound to DR52c, engaged the TCR and activated ANi2.3 T cells in the absence of Ni 2+ (Yin et al., 2012) . The mimotope p7 lysine was suggested to mimic Ni 2+ in the natural TCR ligand, and MHCII β chain flexibility in the area around the peptide p7 position forms a common site for cation binding in metal allergies. Fluorescently labeled MHC-peptide tetramers are powerful tools in the analysis of antigen-specific T cell immune responses (Nepom, 2012) . The goal of our research was to use the DR52c/Ni 2+ mimotope tetramers to study Ni 2+ sensitized patients with joint implant failure, and thus provide insight into the Ni 2+ sensitization process. The subjects in this study were referred by their orthopedic surgeon for Toxicology and Applied Pharmacology 331 (2017) 69-75 evaluation as to whether sensitization to an implant component had contributed to their joint replacement failure. They were determined to be Ni 2+ sensitized by both patch testing and blood lymphocyte proliferation test (LPT), and to have a Ni 2+ containing implant (Pacheco et al., 2013) . To date, it has been difficult to study how Ni 2+ haptens are incorporated into self-peptide and became T cell epitopes for several reasons. First, the binding affinity between TCRs and the peptide-Ni 2+ ligands is low (Yin et al., 2012) . Second, the metal binding sites are commonly solvent exposed and heavily influenced by the media or buffers.
In previous baculovirus DR52c-peptide library screening experiments, we showed that the εNH2 group of lysine mimicked the Ni 2+ ions in the engagement of TCRs with stronger and more stable binding (Yin et al., 2012 
Material and methods

Subject selection
Subjects were enrolled in an IRB approved metal allergy study after providing written informed consent. We randomly selected the initial 4 subjects in our study on the basis of a positive Ni 2+ patch test and a pos- (Moulon et al., 1995) , only Caucasian subjects were selected.
Cell lines
The Ni 2+ reactive CD4 + T cell transfectoma bearing Vα and Vβ TCR segments of ANi2.3 T cell, and Cα and Cβ segments of a mouse TCR, has been described previously (Vollmer et al., 1999) .The EBV transformed B cell line, HO301, expresses DRB3*0301 (DR52c), DRA*01012, DRB1*1302, DQA*101021, DQB1*0604, DPA1*01, and DPB1*1601 (Gorski et al., 1989; Lu et al., 2003) . The two cell lines are gifts of Dr. John Kappler (National Jewish Health, Denver, CO).
Monoclonal antibodies
FK7.3.19.1 is a monoclonal antibody (mAb) specific for DR52 (also cross-reactive to DRB1*0301 and DRB1*0302) (Bontrop et al., 1990) . Biotin mouse IgG2b κ was from PharMingen (03042C). Tetramer staining used the following MAbs: Streptavidin-R-Phycoerythrin (PE)/Cy7anti-human CD4 antibody (Biolegend, 300511); StreptavidinAllophycocyanin (APC)/Cy7 anti-human CD8 antibody (Biolegend, 344713); PE anti-human CD8 antibody (for single staining for PE tetramer, Becton Dickinson, 7317); APC anti-human CD8a antibody (for single staining for APC tetramer, eBioscience, 17-0088-41); PB antihuman CD14 antibody (Caltaglab, MHCD1428); BV421 anti-human CD19 antibody (BD, 562441); PerCP/Cy5.5anti-human/mouse CD44 antibody (eBioscience, 45-0441); BV605 anti-human CD3 antibody (Biolegend, 327321); HLA typing antibody: BV605 anti-human CD3 antibody (Biolegend, 327321); PerCP anti-human CD14 antibody (BD, 340585); BV421 anti-human CD19 antibody (BD, 562441); Others: FITC anti-human TCR Vβ17 antibody (Beckman Coulter, IM1234).
Reagents
Purified human Fc receptor binding inhibitor (eBioscience, 45-0441). PE-SA for detecting biotin-Ab in flow cytometry (Molecular Probes, S-866). Phytohemagglutinin-L (PHA-L) solution (500 ×-,eBioscience, 00-4977). Ficoll (Ficoll-paque™ PLUS, GE Healthcare, 17-1440-03). PE (ProZyme, PJRS25) and APC (ProZyme, PJ25S) for making tetramers.
Preparation of soluble DR52c with Ni
2+ mimotope peptide and Ni
2+ mimotope peptide-DR52c tetramers
The DR52c α and β chains were cloned into a two-promoter baculovirus transfer vector described previously (Dai et al., 2008) . Briefly, the DNA encoding a DR52c-binding Ni 2+ mimotope peptide followed by a linker (GPSKVATLVPRGSGGGGS) was inserted into the frame between the signal peptide and the N terminus of the DR52c β chain, such that after expression and signal peptide cleavage, the peptide would occupy the peptide-binding groove of DR52c (Kozono et al., 1994) . Three mimotope peptides were chosen to make tetramers: QHIRCNIPKRI (pHIR), QWIRVNIPKRI (pWIR) and QHISINLPKRI (pHIS). The final construction was sequenced and then transfected SF9 insect cells using standard homologous recombination and Baculogold (PharMingen) as the recipient baculovirus DNA. Then the virus was expanded to provide a high-titer stock for large-scale production of DR52c-mimotope peptides.
To prepare protein for the tetramers, 4 l of Hi-5 insect cells (≈ 5 × 10 5 /ml) were infected at a multiplicity of infection of ≈ 5. After 5 days, the culture supernatant was collected by centrifugation and passed through a 0.2-μm filter. The soluble DR52c-mimotope peptides were isolated from the supernatant by anti-DRα-specific mAb LB3.1 affinity column (American Type Culture Collection). The eluate from the column was concentrated and further purified in a Superdex-200 sizeexclusion chromatograph. The homogeneous peak corresponding to a molecular mass of ≈60 KD was collected. The proteins were biotinylated with BirA (Avidity, Denver) and incorporated into saturated complexes with PE or APC as described previously (Crawford et al., 1998) .
PBMC preparation and cryopreservation
Blood was separated on a Ficoll Hypaque gradient, according to standard methods. In brief, the blood was diluted 1:1 with PBS (≤40 ml) and slowly added onto 10 ml of Ficoll in 50 ml conical tube. The tube was spun at 740 g for 20 min. The buffy coat layer (PBMC) was carefully transferred into a new tube by pipette, and an equal volume of PBS was added. The tube was centrifuged at 350 g for 10 min, and the supernatant was discarded. 10 ml of fresh PBS was added, and 10 μl of sample was used for cell quantification. The tube was again centrifuged at 350 g for 10 min. PBMCs weresuspended in 10% DMSO and 90% FBS at a concentration of 5-10 million cells/ml in 1 ml aliquots. The cells were frozen at − 80°C for 2-3 days, and then were transferred into liquid nitrogen until used in experiments.
DR52 typing
The B cells from patients' PBMCs were stained with bio-FK7.3.19.1, followed by binding to PE conjugated Streptavidin. In the flow cytometry experiments, 5 million PBMCs were used for each sample. For single staining samples, 10 thousand PBMCs were used. After PBMCs were thawed, they were washed once with balanced salt solution (BSS). PBMCs were stained with BV605 anti-human CD3 antibody, PerCP anti-human CD14 antibody, BV421 anti-human CD19 antibody, and bio-FK7.3.19.1 or bio-mouse IgG2b at 4°C for 20-30 min. Cells were then washed three times with BSS. The cells were stained with PE-SA at 4°C for 20-30 min, and washed with BSS three times. Cells were fixed by 1% parafomaldehyde for 20 min at room temperature, then washed twice and analyzed by flow cytometry (CyAn ADP, Beckman Coulter). The data were analyzed by FlowJo v8.8.7.
PBMC T cell stimulation
10 million thawed PBMCs were washed once with BSS, and then cultured in CTM (complete tumor medium, MEM enriched with essential and nonessential amino acids, glutamine, sodium bicarbonate, 10% fetal bovine serum, and 20 μM 2-mercaptoethanol). For Ni 2+ activation, 10 −4 M NiSO 4 was added to cells and cultured for 7-8 days before staining and analyzed by flow cytometry. During the 7-8 days, the culture medium with Ni 2+ was exchanged once. For PHA-L activation, cells were activated by 1 × PHA-L for 3 days, followed by another 4-5 days in culture media without PHA-L.
2.9. Immunofluorescence analysis for DR52c/Ni 2+ mimotope tetramer binding
In the tetramer staining of T transfectoma cells, 1 million cells were stained with tetramers (20 μg/ml) at 37°C for 2 h. To enhance peptide-MHC tetramer binding, separate samples also included mAb H597 specific to murine Cβ (Kubo et al., 1989) (Yin et al., 2012) . We chose the mimotopes that best stimulated ANi2.3 T cell (pHIR, pWIR and pHIS) to make tetramers. The soluble mimotope-DR52c molecules were expressed and purified. A BirA tag was present in the C terminal of the β chain of DR52c. The soluble mimotope-DR52c molecules could be made into biotinylated version of complexes. Tetramers were prepared by ligating PE-streptavidin or APC-streptavidin to the biotinylated peptide-DR52c molecules.
To test the binding and specificity of the covalent mimotope-DR52c complexes, we used ANi2.3 T cell transfectomas as a positive control. These transfectomas responded to autologous antigen-presenting cells pulsed with Ni 2+ (Vollmer et al., 2000; Lu et al., 2003) . The ANi2.3 T cells and control cells were incubated with tetramers linked to pHIR, pHIS, pWIR and pTu peptides, respectively. pTu is an irrelevant peptide that served as a negative control (Fig. 1) . PE-tetramers with pHIR, pHIS and pWIR peptides and APC-tetramer with pHIR peptide could specifically stain the ANi2.3 T cells but not the control cells; PE-tetramer with pTu peptide could not stain the ANi2.3 T cells. (Fig. 1A-D) . The anti-mouse Cβ mAb, HAM 597, enhanced the staining of Ni 2+ mimotope tetramers ( Fig. 1E and F (Fig. 2B) . The isotype control (bio-mouse IgG2b κ) does not stain B cells (Fig. 2B ). In the 4 selected patients, patient KR, BS and RB are DR52 positive, and patient LJ is DR52 negative. Fig. 3A and B left) . In contrast, the control DR52c-pTu tetramer staining of the CD4 + T cell population was almost undetectable (Fig. 3A and B, right). PHA-L can induce non-specific proliferation of T cells, and in the PHA-L stimulated positive controls, the DR52c pHIR tetramer staining is much lower than that seen with Ni 2+ stimulation (Fig. 3C ). CD44 expression is an indicative marker for effector-memory T-cells. As shown in Fig. 3 , in patient KR, the tetramer-positive cells after Ni 2+ stimulation were CD44 high CD4 + and CD44 low CD4 + T cells, while the cells after PHA-L stimulation were CD44 low CD4 + T cells ( Fig. 3B and C). It implies that the DR52c-pHIR positive CD4 + T cells in the Ni 2+ stimulated patient were Ni 2+ nickel specific. These results demonstrate that the DR52c-pHIR tetramer can specifically detect Ni 2+ reactive T cells (Fig. 3A, B and C) . The percentage of Vβ17 T cells increased in tandem with tetramer staining after Ni 2+ stimulation, which was not observed in the PHA-L stimulated controls (Fig. 3D, E and F) . We then examined DR52c-pHIR tetramer binding of PBMCs stimulated by Ni 2+ from 4 Ni 2+ sensitized patients with implant failure (Fig. 4A) . The two-color tetramer staining was similar to one-color staining. Patient KR is HLA-DR52 positive, and demonstrated the greatest DR52c-pHIR tetramer staining, accounting for 1.09% in one color staining (Fig. 3B and Fig. 4A ). The percentage of TCR Vβ17 staining also increased from b 1% to 13.3% after Ni 2+ stimulation for this patient, demonstrating a significantly increased proportion of T cells specific to Ni 2+ expressing this beta chain (Fig. 4B ). For the other three patients, tetramer staining and Vβ17 percentages remained low ( Fig. 4A-B) . We used a DR52 specific mAbFK-7.3.19.1 to type the patients. HLA DR52 has three sub-alleles: DR52a, DR52b, and DR52c (Dai et al., 2008) . In fact, the three DR52 alleles are closely related, as they derive from a common precursor gene through a gene conversion or other type of recombination event (Gorski and Mach, 1986; Gorski et al., 1989) . Their sequence data suggest that DR52c was derived from a recombination between DR52a and DR52b (Gorski et al., 1989) . It is possible that our DR52c-pHIR tetramer could also cross-react with Ni 2+ specific T cells from DR52a or DR52b positive patients. The similarity of certain peptide-binding pockets between DR52c, DR52b and DR52a, may explain why certain autoimmune diseases are associated with two of the three alleles; depending on the relative use of particular binding sites, a given peptide might bind to more than one of these DR52 allelic forms (Dai et al., 2008) .
In our small sample of four patients with implant failure due to Ni 2+ sensitization, the combined DR52 frequency is 75% (Fig. 2B ). This is similar to the frequency of HLA DR52 in a study of Ni 2+ allergy in contact dermatitis, where the combined DR52 frequency was 66.7% (Vollmer et al., 1997) . Interestingly, it is much higher than the frequency of HLA DR52 in the general Caucasian population, where it is 38.7% (www. allelefrequencies.net).
In another example of the immune specificity of metal sensitization, Beryllium (Be 2+ ) hypersensitivity is linked to a Glu 69 present in the DP2 beta chain (Dai et al., 2010) . Here, we showed that the Be 2+ ion was buried in the acidic pocket between MHC and self-peptides (Clayton et al., 2014) , which limits the alleles of Be 2+ presenting MHC molecules. In contrast, Ni 2+ presentation is far more promiscuous, since Ni 2+ ions are coordinated on top of MHC molecules and selfpeptides (Yin et al., 2012) . As long as the amino acids on the face of MHC and self-peptides satisfy the Ni 2+ coordination chemistry, quite diverse MHCs and peptides could present Ni 2+ to T cells. Vollmeret al.
showed that DR52c was not the only MHC restriction element for Ni 2+ reactive CD4 + T cells (Vollmer et al., 1999) .
In summary, we have demonstrated that the DR52c-pHIR tetramer specific to one Ni 2+ clone was able to also detect Ni 2+ specific CD4 + T cells in other sensitized patients. These tetramers can provide a powerful tool to study T cells from Ni 2+ allergic patients, and could potentially develop into a clinically useful biomarker. Using this patient population, we plan to study the exact peptides associated with Ni 2+ reactive TCRs by isolating tetramer-positive CD4 + T cells, and determining TCR usage using single cell sequencing.
